Cargando…
Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as inoperable/difficult-to-reach lesions or rela...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470698/ https://www.ncbi.nlm.nih.gov/pubmed/34577572 http://dx.doi.org/10.3390/ph14090872 |
_version_ | 1784574266809778176 |
---|---|
author | Cimini, Andrea Ricci, Maria Russo, Francesca Egidi, Martina Calabria, Ferdinando Bagnato, Antonio Schillaci, Orazio Chiaravalloti, Agostino |
author_facet | Cimini, Andrea Ricci, Maria Russo, Francesca Egidi, Martina Calabria, Ferdinando Bagnato, Antonio Schillaci, Orazio Chiaravalloti, Agostino |
author_sort | Cimini, Andrea |
collection | PubMed |
description | Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as inoperable/difficult-to-reach lesions or relapsing disease. In regard to the last point, malignant primary brain tumors remain some of the most lethal types of cancer. Nuclear medicine may provide exciting new weapons and significant contributions in the treatment of PBTs. In this review, we performed literature research in order to highlight the possible role of peptide receptor radionuclide therapy (PRRT) in the treatment of PBTs with radiolabeled molecules that bind with high-affinity transmembrane receptors such as somatostatin receptors (SSTRs), neurokinin type-1 receptor and prostate-specific membrane antigen (PSMA). These receptors are overexpressed in some cancer types such as gliomas, meningiomas, pituitary tumors and medulloblastomas. A comprehensive overview of possible applications in this field will be shown, providing knowledge about benefits, feasibility, developments and limitations of PRRT in this type of tumor, also revealing new advantages in the management of the disease. |
format | Online Article Text |
id | pubmed-8470698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84706982021-09-27 Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview Cimini, Andrea Ricci, Maria Russo, Francesca Egidi, Martina Calabria, Ferdinando Bagnato, Antonio Schillaci, Orazio Chiaravalloti, Agostino Pharmaceuticals (Basel) Review Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as inoperable/difficult-to-reach lesions or relapsing disease. In regard to the last point, malignant primary brain tumors remain some of the most lethal types of cancer. Nuclear medicine may provide exciting new weapons and significant contributions in the treatment of PBTs. In this review, we performed literature research in order to highlight the possible role of peptide receptor radionuclide therapy (PRRT) in the treatment of PBTs with radiolabeled molecules that bind with high-affinity transmembrane receptors such as somatostatin receptors (SSTRs), neurokinin type-1 receptor and prostate-specific membrane antigen (PSMA). These receptors are overexpressed in some cancer types such as gliomas, meningiomas, pituitary tumors and medulloblastomas. A comprehensive overview of possible applications in this field will be shown, providing knowledge about benefits, feasibility, developments and limitations of PRRT in this type of tumor, also revealing new advantages in the management of the disease. MDPI 2021-08-29 /pmc/articles/PMC8470698/ /pubmed/34577572 http://dx.doi.org/10.3390/ph14090872 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cimini, Andrea Ricci, Maria Russo, Francesca Egidi, Martina Calabria, Ferdinando Bagnato, Antonio Schillaci, Orazio Chiaravalloti, Agostino Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview |
title | Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview |
title_full | Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview |
title_fullStr | Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview |
title_full_unstemmed | Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview |
title_short | Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview |
title_sort | peptide receptor radionuclide therapy and primary brain tumors: an overview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470698/ https://www.ncbi.nlm.nih.gov/pubmed/34577572 http://dx.doi.org/10.3390/ph14090872 |
work_keys_str_mv | AT ciminiandrea peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview AT riccimaria peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview AT russofrancesca peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview AT egidimartina peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview AT calabriaferdinando peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview AT bagnatoantonio peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview AT schillaciorazio peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview AT chiaravallotiagostino peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview |